CUREator+ awards US$8.74M in grants to six Australian health startups

What's the deal? Six Australian biomedical and health technology startups have been awarded a combined US$8.74M through the second funding round of CUREator+, a non-dilutive commercialisation program delivered by Brandon BioCatalystDealroom has a profile for this one. Try Dealroom → with ANDHealth and supported by Australia's Medical Research Future Fund.

Who got what? Aleris TherapeuticsDealroom has a profile for this one. Try Dealroom →, Frontier Inflammasome Therapeutics, and Luma Bio each received US$1.62M. Navier MedicalDealroom has a profile for this one. Try Dealroom → received US$1.38M, NeurotologixDealroom has a profile for this one. Try Dealroom → received US$1.26M, and WeGuideDealroom has a profile for this one. Try Dealroom → received US$1.26M.

What are they building? The recipients are developing therapies for inflammatory disease and cancer, AI-enabled cardiac risk markers, a platform for assessing vertigo and dizziness, and digital biomarkers based on wearable, clinical, and patient-generated health data.

Read more: DistilINFO · Brandon BioCatalyst